Validation of National Institutes of Health Global Scoring System for Chronic Graft- Versus-Host Disease (GVHD) According to Overall and GVHD-Specific.

Slides:

Advertisements

Similar presentations

Clinical Evaluation of Oral Chronic Graft-Versus-Host Disease

Advertisements

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

Incidence and Prognostic Value of Eosinophilia in Chronic Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation Imran Ahmad,

Prognostic Factors of Chronic Graft-versus-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation: The National Institutes Health.

Prognostic Power of Chronic Gvhd Risk Score Model by Ibmtr Can Be Improved with Addition of Absolute Lymphocyte Counts and Eosinophil Counts At the Onset.

Pre-Engraftment Syndrome after Unrelated Cord Blood Transplantation: A Predictor of Engraftment and Acute Graft-versus-Host Disease Meerim Park, Soo.

Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease

A Prospective Study Comparing the Outcomes and Health-Related Quality of Life in Adult Patients with Myeloid Malignancies Undergoing Allogeneic Transplantation.

A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft- versus-Host Disease Alex F. Herrera, Haesook T. Kim, Bhavjot Bindra,

Incidence and Risk Factors for Early Hepatotoxicity and Its Impact on Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell.

Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Aazim K. Omer, Daniel J. Weisdorf, Aleksandr Lazaryan,

Implementation of Post-Transplant Assessment Tools for Improved Accuracy of Graft- Versus-Host Disease Reporting Madhu Ragupathi, Jaskiran Kaur, Luda.

Oral Manifestations Compatible with Chronic Graft-versus-Host Disease in Patients with Fanconi Anemia Laura Grein Cavalcanti, Renata L. Fuentes Araújo,

Sabina Kersting, Leo F. Verdonck

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation

Musculoskeletal, Neurologic, and Cardiopulmonary Aspects of Physical Rehabilitation in Patients with Chronic Graft-versus-Host Disease Sean Robinson.

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival Mary.

Outcomes of Hematopoietic Cell Transplantation in Adult Patients with Acquired Aplastic Anemia Using Intermediate-Dose Alemtuzumab-Based Conditioning

Impact of Ocular Chronic Graft-versus-Host Disease on Quality of Life

Re: Twenty-Year Follow-Up in Patients with Aplastic Anemia Given Marrow Grafts from HLA-Identical Siblings and Randomized to Receive Methotrexate/Cyclosporine.

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

Pulse Cyclophosphamide for Steroid-Refractory Chronic Graft-Versus-Host Disease Nelson J. Chao, MD, MBA, Yevgeniya Gora Foster, MD, Krista Rowe, RN, MSN,

Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302 Javier Bolaños-Meade, Juan Wu, Brent R. Logan,

Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation—Results from a Single-Center Observational Study

Successful Prevention of Acute Graft-versus-Host Disease Using Low-Dose Antithymocyte Globulin after Mismatched, Unrelated, Hematopoietic Stem Cell Transplantation.

Helicobacter pylori Infection and Graft-versus-Host Disease

Benefit of Allogeneic Transplantation in Patients Age ≥ 60 Years with Acute Myeloid Leukemia Is Limited to Those in First Complete Remission at Time of.

Oral Chronic Graft-versus-Host Disease Scoring Using the NIH Consensus Criteria Nathaniel S. Treister, Kristen Stevenson, MS, Haesook Kim, Sook-Bin Woo,

Classic and Overlap Chronic Graft-versus-Host Disease (cGVHD) Is Associated with Superior Outcome after Extracorporeal Photopheresis (ECP) Madan H. Jagasia,

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

Can Only Partial T-Cell Depletion of the Graft before Hematopoietic Stem Cell Transplantation Mitigate Graft-versus-Host Disease While Preserving a Graft-versus-

Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma John Kuruvilla, Gregory Pond, Richard.

Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease Caron A. Jacobson, Lixian Sun, Haesook.

Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning

A Comparison of Long-Term Outcomes of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors in Patients With Relapsed CML After Allogeneic Hematopoietic.

Moderate/Severe Grade of Chronic Graft Versus Host Disease and Younger Age (Less Than 45 Years Old) Are Risk Factors for Avascular Necrosis in Adult Patients.

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-versus-Host Disease.

Possible Association between Obesity and Posttransplantation Complications Including Infectious Diseases and Acute Graft-versus-Host Disease Shigeo Fuji,

Similar Outcomes of Cryopreserved Allogeneic Peripheral Stem Cell Transplants (PBSCT) Compared to Fresh Allografts Dong Hwan Kim, Nazir Jamal, Ronnie.

Myeloablative Transplantation using either Cord Blood or Bone Marrow leads to Immune Recovery, High Long-Term Donor Chimerism and Excellent Survival in.

ASBMT and CBMTG Release Choosing Wisely BMT Recommendations

Kinetics and Risk Factors of Relapse after Allogeneic Stem Cell Transplantation in Children with Leukemia: A Long-Term Follow-Up Single-Center Study

Diarrhea during the Conditioning Regimen Is Correlated with the Occurrence of Severe Acute Graft-versus-Host Disease through Systemic Release of Inflammatory.

Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Manifestations, and Clinical Significance Deborah.

Nonmyeloablative Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients 60 Years or Older Vikas Gupta, Andrew Daly,

Chronic Graft-Versus-Host Disease (cGVHD) following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate In Recipients.

Peripheral Blood Eosinophilia Has a Favorable Prognostic Impact on Transplant Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation Dong.

Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews Emily C. Merkel, Sandra A. Mitchell,

Unrelated Stem Cell Transplantation after a Reduced Intensity Conditioning Regimen Containing High-Dose Thymoglobulin Leads to Controllable Graft-versus-Host.

Incidence and Risk Factors for Nontuberculous Mycobacterial Infection after Allogeneic Hematopoietic Cell Transplantation Jennifer Beswick, Elizabeth.

John E. Levine, Sophie Paczesny, Stefanie Sarantopoulos

Improved Outcome for Peripheral Blood Stem Cell Transplantation for Advanced Primary Myelodysplastic Syndrome Scott R. Solomon, Bipin N. Savani, Richard.

A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell.

Manuel Jurado, Carlos Vallejo, José A

A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality Margaret.

Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation.

Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.

Preengraftment Syndrome after Unrelated Cord Blood Transplant Is a Strong Predictor of Acute and Chronic Graft-versus-Host Disease Haydar Frangoul, Li.

Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Twenty-Year Follow-Up of a Controlled Trial Comparing a Combination of Methotrexate Plus Cyclosporine with Cyclosporine Alone for Prophylaxis of Graft-versus-Host.

Incidence and Outcome of Chronic Graft-versus-Host Disease Using National Institutes of Health Consensus Criteria Madan Jagasia, Jennifer Giglia, Wichai.

Treatment versus Transplant for Challenging Hematologic Disorders

Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.

Oral Symptom Intensity, Health-Related Quality of Life, and Correlative Salivary Cytokines in Adult Survivors of Hematopoietic Stem Cell Transplantation.

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Infliximab for Managing Steroid-Refractory Acute Graft-versus-Host Disease Joseph Pidala, Jongphil Kim, Teresa Field, Ali McBride, Mohamed Kharfan-Dabaja,

Graft-versus-Tumor Effect According to Type of Graft-versus-Host Disease Defined by National Institutes of Health Consensus Criteria and Associated Outcomes

Biology of Blood and Marrow Transplantation

Presentation transcript:

Validation of National Institutes of Health Global Scoring System for Chronic Graft- Versus-Host Disease (GVHD) According to Overall and GVHD-Specific Survival Joon Ho Moon, Sang Kyun Sohn, Anna Lambie, Laura Ellis, Nada Hamad, Jieun Uhm, Vikas Gupta, Jeffrey H. Lipton, Hans A. Messner, John Kuruvilla, Dennis Kim Biology of Blood and Marrow Transplantation Volume 20, Issue 4, Pages 556-563 (April 2014) DOI: 10.1016/j.bbmt.2014.01.010 Copyright © 2014 Terms and Conditions

Figure 1 OS according to the RSC (A) and to the subtype of cGVHD by NIH criteria (B) and GSS according to the RSC (C) and to the subtype of cGVHD by NIH criteria (D). (A) Five-year OS rate was 73.9% ± 6.0% for patients with limited cGVHD and 64.1% ± 3.3% for patients with extensive cGVHD (P = .017). (B) Five-year OS for patients with classic cGVHD (81.0% ± 3.9%) and overlap syndrome (67.7% ± 3.9%) was significantly different (P = .004). (C) Five-year GSS rate was significantly worse for patients with extensive cGVHD (73.3% ± 3.1%) than for patients with limited cGVHD (97.6% ± 1.7%, P < .001). (D) Five-year GSS rate for patients with classic cGVHD (94.5% ± 2.2%) and overlap syndrome (78.3% ± 3.5%) was significantly different (P < .001). Biology of Blood and Marrow Transplantation 2014 20, 556-563DOI: (10.1016/j.bbmt.2014.01.010) Copyright © 2014 Terms and Conditions

Figure 2 OS according to NIH severity at onset (A) and at peak (B) and GSS according to NIH severity at onset (C) and at peak (D). (A) Five-year OSrate was significantly worse for severe global severity at onset: 48.5% ± 7.8% for severe versus 70.1% ± 5.0% for moderate versus 83.2% ± 3.6% for mild (P = .001). Difference between mild and moderate groups was modest (P = .064). (B) Five-year OS rate was significantly worse for severe global severity at peak: 61.5% ± 5.2% for severe versus 76.1% ± 3.9% for moderate versus 90.5% ± 5.3% for mild (P < .001). No difference was observed between mild and moderate groups (P = .151). (C) Five-year GSS rate at onset was significantly worse for patients with severe global severity (50.9% ± 7.8%) than for patients with moderate (89.7% ± 3.2%) and mild (93.5% ± 2.4%, P < .001) grades. No differences in GSS was noted between moderate and mild grades of cGVHD at onset (P = .452). (D) Five-year GSS rate at onset was significantly inferior for patients with severe global severity (69.1% ± 5.2%) than for patients with moderate (93.2% ± 2.1%) and mild (97.3% ± 2.7%, P < .001) grades. No differences in GSS were noted between moderate and mild grades of cGVHD at peak (P = .474). Biology of Blood and Marrow Transplantation 2014 20, 556-563DOI: (10.1016/j.bbmt.2014.01.010) Copyright © 2014 Terms and Conditions

Figure 3 (A) Five-year CIR was significantly higher for patients with limited cGVHD (23.1% ± .2%) than for patients with extensive cGVHD (11.9% ± .1%, P = .002). (B) Five-year CIR was 17.3% ± 1.3% for classic cGVHD and 12.5% ± .7% for overlap syndrome (P = .228). (C) Five-year CIRs at onset among NIH severity groups were 11.7% ± .9% for mild, 19.3% ± 1.4% for moderate, and 9.6% ± 2.2% for severe (P = .129). (D) Five-year CIRs at peak among NIH severity groups were 11.7% ± .9% for mild, 19.3% ± 1.4% for moderate, and 9.6% ± 2.2% for severe (P = .203). Biology of Blood and Marrow Transplantation 2014 20, 556-563DOI: (10.1016/j.bbmt.2014.01.010) Copyright © 2014 Terms and Conditions